When will the patents on HYDREA expire, and when will HYDREA go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Waylis Therap	HYDREA	hydroxyurea	CAPSULE;ORAL	016295-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 30, 2026

HYDREA (hydroxyurea) investment scenario and fundamentals analysis: exclusivity, generic risk, and revenue/market outlook

HYDREA (hydroxyurea) is an established, off-patent oncology and hematology drug with low exclusivity value and high generic penetration risk across major markets. For investment decisions, the key fundamentals are: (1) long-run demand stability driven by chronic indications, (2) pricing pressure and margin compression from authorized and unbranded generics, and (3) limited upside from incremental patent estates because most hydroxyurea IP is either expired or weakly actionable versus generic formulations and manufacturing.

What is HYDREA and what indications drive demand?

Hydroxyurea is used primarily in myeloproliferative neoplasms (notably polycythemia vera and essential thrombocythemia) and in oncology support settings such as sickle cell disease in select label geographies. In the US, HYDREA is referenced for the hematology oncology indications in its FDA-approved labeling.

Core demand drivers

Chronic dosing patterns for hematology patients.
Wide clinician familiarity and entrenched formularies.
Competitive behavior dominated by generic entry and contracting dynamics rather than brand differentiation.

Value chain reality

HYDREA’s investment profile depends less on blockbuster growth and more on defending a residual brand footprint against generics and authorized generics, managing payer mix, and limiting distribution losses.

When does HYDREA lose exclusivity, and what is the generic entry risk?

HYDREA’s commercial protection is not the main lever. Hydroxyurea as an active ingredient has long commercial history, and the practical exclusivity landscape is dominated by generic availability, formulation substitutions, and manufacturing process workarounds rather than brand-new regulatory exclusivities.

US exclusivity framework (practical interpretation for hydroxyurea)

Brand exclusivity for hydroxyurea products has already run its course in prior cycles.
Any remaining brand protection typically comes from narrow formulation/device/packaging or method-of-use patents, which are often not strong enough to stop ANDA-level competition for a simple oral cytotoxic.

Generic risk assessment

High.
Label-level competition is structurally enabled because hydroxyurea is not a novel molecular entity with modern biologic-style exclusivity barriers.
Market entry tends to be fast once patent and exclusivity barriers clear.

Investor implication

Base-case returns should assume continuous price erosion, with upside limited to share defense and contracted rebates rather than monopoly pricing.

What patents protect HYDREA, and how strong is the patent estate?

Hydroxyurea itself is a mature small molecule. HYDREA’s protectable scope, if any, typically sits in older, narrow categories:

Formulation patents (e.g., tablet/capsule composition and/or excipient system)
Manufacturing method patents
Specific dosing regimen or method-of-use patents for particular patient subgroups

Investment relevance

For established cytotoxics, patent estates often end up acting as a timing tool for generic entry rather than a durable margin shield.
Any remaining patents are likely to be fragmented across jurisdictions and claim scope, making enforcement expensive relative to incremental revenue.

Practical bottom line

The risk-adjusted probability of sustained brand exclusivity is low.
IP value is highest only if (a) a relevant method-of-use patent is active, and (b) generic challengers cannot easily design around.

What formulations are protected by HYDREA patents (tablets, dose forms, excipients)?

Oral solid dosage protection (composition and excipient systems) can sometimes delay generic substitution if claims are specific and not easily designed around. For a mature active ingredient like hydroxyurea, generic developers often target:

Different excipient compositions
Different granulation processes
Alternative manufacturing controls

Investor impact

If HYDREA’s remaining protection is limited to excipient/formulation details, generics can design around with routine formulation changes.
If protection includes manufacturing methods that must be replicated exactly, generic entry can be slower but still feasible via alternative process development.

What Orange Book status does HYDREA have?

HYDREA’s Orange Book status is the central database proxy for FDA-recognized patents and exclusivities. For an active ingredient with long market tenure, the expected pattern is:

Minimal active patents listed
Short remaining runways or non-blocking patents that do not prevent ANDA approval

Commercial implication

Where Orange Book lists are thin or old, generic approvals proceed with limited litigation friction.
Where Orange Book listings exist but are narrow, the economic barrier to generic entry remains low.

What patent litigation affects HYDREA and generic entry scenarios?

For mature, small-molecule products, litigation typically clusters around:

Paragraph IV certifications tied to the Orange Book patent lists
Alleged infringement of formulation or method claims
Settlement agreements that delay entry by months to years depending on patent strength

Investor conclusion

HYDREA’s investment case should treat litigation outcomes as a timing variable, not as a structural moat.
If no meaningful active patents remain, the generic entry path becomes procedural and pricing-driven.

How does HYDREA compare with competing hydroxyurea brands and generics?

In hydroxyurea markets, competitive dynamics are dominated by:

Authorized generics and branded generic “private label” distribution
Direct-to-payer contracting and formulary placement
Coupon and patient support diminishing as generics undercut net pricing

Competitive positioning

HYDREA’s brand value tends to be anchored in supply reliability and prescriber familiarity.
Generic competitors typically price to win rebates and formulary access.

Investor implication

A brand’s unit share is defendable only if net prices and patient access programs compensate for generic undercutting.

What is the FDA regulatory status of HYDREA (ANDA vs. reference product stability)?

HYDREA, as an FDA-approved reference product, supports ANDA pathways for generic hydroxyurea. Because hydroxyurea is widely used and already established, generic approvals commonly proceed without novel clinical data.

Regulatory economics

ANDA economics are driven by bioequivalence and manufacturing validation rather than clinical trials.
That accelerates competitive entry once IP barriers lift.

Investor bottom line

Regulatory pathway maturity increases entry velocity and compresses the brand’s pricing power.

What biologic or biosimilar risk applies to HYDREA?

None. HYDREA is a small molecule; biosimilar frameworks do not apply.

Investment implication

Risk modeling should focus on ANDA/generic competition, not biosimilar interchange or RMAT/REMS-driven exclusivity.

How do manufacturing and IP barriers affect generic substitution for HYDREA?

Manufacturing barriers matter when:

Patents cover specific manufacturing methods that are non-trivial to replicate
Controls require higher cost or tight process windows
Supply constraints create temporary shortages where brand may retain share

For established cytotoxics, manufacturing barriers are usually surmountable:

Hydroxyurea is synthesized and formulated at scale globally.
ANDA applicants can develop equivalent processes and pass inspection.

Investor conclusion

Production scale and quality compliance dominate, not process-specific IP.

What settlement agreements matter for HYDREA and when do they change the market?

Where Orange Book patents exist, settlement agreements can:

Delay generic launches under agreed terms
Include provisions affecting supply, exclusivity carve-outs, or “worksharing” among ANDA applicants

Investment modeling approach

Treat settlements as short-to-medium horizon events that affect launch timing and early market share.
Build scenarios around “generic enters soon,” “generic enters after delay,” and “no settlement, immediate litigation outcome.”

Investment scenario: base case, downside, and upside for HYDREA

Base case (most likely)

Continued share erosion to generics.
Net price declines driven by payer contracting.
Brand profits stabilize only if HYDREA retains volume via supply reliability and formulary status.

Where upside comes from

Execution improvements in payer mix.
Minimal incremental competitive entrants.
Conservative manufacturing planning that reduces stock-outs.

Downside case

Accelerated generic launches aligned with patent expiry or non-asserted Orange Book listings.
Increased rebate pressure and broader formulary substitution.
Margin compression plus higher administrative costs tied to contracting and distribution.

Upside case (less likely, requires a favorable IP/contracting outcome)

Any remaining enforceable, claim-relevant patent blocks or meaningfully delays generic substitution.
Strong payer retention due to patient program or improved supply performance.
Litigation and regulatory outcomes limit entry timing.

Key commercialization levers for investing in HYDREA

Net price retention vs. wholesale acquisition cost exposure.
Contract coverage durability: managed care channel penetration and state Medicaid positioning.
Supply chain resilience to avoid shortages.
Portfolio strategy: whether HYDREA remains a “cash engine” product that funds broader pipelines, or is deprioritized as competition increases.

Key takeaways

HYDREA’s investment profile is dominated by structural generic competition risk, not long-lived exclusivity.
Expect persistent pricing pressure and share migration toward lower-cost alternatives.
Any remaining patent value is likely narrow and more relevant to launch timing than durable margins.
Fundamentals should be modeled as a declining brand trajectory with opportunities limited to payer contracting, supply reliability, and execution.

FAQs

1) Is HYDREA still a good investment if hydroxyurea is widely generic?

Given the mature active ingredient and typical ANDA entry economics, the investment case depends on protecting net pricing and formulary access, not on expecting sustained exclusivity premiums.

2) What are the biggest drivers of HYDREA net sales decline in a generic scenario?

Payer rebate escalation, formulary substitution, and broader switching at the pharmacy counter.

3) Are method-of-use patents more likely to matter than formulation patents for HYDREA?

If they exist and remain active, method-of-use claims can be more blocking than formulation claims, but they still tend to be time-limited for mature small molecules.

4) How should investors model launch timing risk for generics of hydroxyurea?

Use Orange Book-anchored timelines, settlement effects, and litigation durations to create scenario-based launch curves rather than a single-point forecast.

5) Does HYDREA face biosimilar-style competition?

No. Hydroxyurea is a small molecule, so competition is via ANDAs and generics, not biosimilars.

References

U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
U.S. Food and Drug Administration. Drug Approval Reports and Labeling for HYDREA (hydroxyurea).

HYDREA Drug Patent Profile

Which patents cover Hydrea, and when can generic versions of Hydrea launch?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Hydrea

AI Deep Research

Questions you can ask:

Summary for HYDREA

US Patents and Regulatory Information for HYDREA